28th Conference on Retroviruses on Opportunistic Infections (CROI 2021)
6–9 March 2021, virtual
This second HTB reports from virtual CROI 2021 include additional good news that from 15 April 2021 the conference will become open access.
i-Base would like to thank the organisers for this decision.
Initially, concerns about funding the conference meant the organisers were planning to keep most of the content behind a pay wall for six months. This would have included abstracts, webcasts and posters.
A community sign-on letter during the first days of the conference included wide support and was successful in having the abstract book posted online. The organising committee have now also reversed their initial plans and agreed that the rest of the rest of the programme, including webcasts, will also now become open access (from 15 April).
CROI 2021 conference materials
The virtual conference was run on a separate website, contents are steadily being transferred to the standard CROI website.
Abstracts from the 2021 meeting are already included in this main database.
Report in this issue include:
- First results against MDR HIV using capsid inhibitor lenacapavir: potential for six-monthly ART and PrEP
- Pregnancy outcomes and weight gain with dolutegravir and TAF
- New compounds for prevention and treatment of COVID-19
- Molnupiravir significantly reduced SARS-CoV-2 viral load after five days in early infection
- Bamlanivimab works as prophylaxis in high risk populations
- Bamlanivimab and etesevimab (Eli-Lilly) reduced hospitalisation and mortality in mild/moderate infection
- Casirivimab and imdevimab (Regeneron) dual mAbs reduce risk of symptomatic transmission
- Presentations from the LEAP workshop 2021
- CROI presentations on NATAP.org